Equity Profile

VCYT

Veracyte, Inc.

Health CareBiotechnology$3.4B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Veracyte, Inc. is a biotechnology company focused on improving patient outcomes through genomic diagnostics....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and is closely watched by investors.

$0.41

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products.

$147M

Wall Street expectations, options signals, track record, and call prep available with Pro.

VCYT Q2-2026 Earnings Preview

Context

Company Snapshot

Veracyte, Inc. is a biotechnology company focused on improving patient outcomes through genomic diagnostics. Operating in the health care sector, Veracyte's innovative tests help physicians make more informed decisions, particularly in cancer diagnosis and treatment, which is increasingly important in today's personalized medicine landscape.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+367.92%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In Q1-2026, Veracyte reported an EPS of $0.52, significantly exceeding analyst expectations. The stock reacted negatively, declining 1.43% the following day despite the strong earnings.

Management Promises & Guidance

Continued focus on expanding its product offerings.
Commitment to improving operational efficiencies.
Plans to enhance market penetration in existing and new territories.

Expectations

Wall Street Expectations

Analysts expect Veracyte to report strong earnings again, building on its recent track record of exceeding EPS estimates. The consensus anticipates a solid revenue figure, reflecting ongoing demand for its diagnostic tests.

Bull Case

If Veracyte beats EPS and revenue estimates, it could reinforce investor confidence and lead to a significant stock price increase, similar to past performance.

Bear Case

Conversely, if the company fails to meet expectations, it could trigger a sell-off, especially given the high implied volatility in the options market.

Key Metrics to Watch

EPS

$0.41

Earnings per share is a key indicator of profitability and is closely watched by investors.

Revenue

$147M

Total revenue gives insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Veracyte's EPS exceed the consensus estimate of $0.41?

Given the company's strong track record of beating EPS estimates, this will be a critical measure of ongoing operational success.

What revenue figure will Veracyte report, and how does it compare to the consensus of $147M?

Revenue performance is essential for assessing market demand and growth potential, especially in a competitive biotech landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Veracyte's ability to leverage its recent innovations and market presence to drive higher-than-expected revenue growth this quarter.

Supporting Evidence

Veracyte has consistently beaten EPS estimates, indicating strong operational execution.

The options market's high implied volatility suggests that investors are anticipating significant movement, which could favor a positive surprise.

Recent trends in the biotech sector show increasing demand for diagnostic tests, which could benefit Veracyte.

Key Risk

If revenue comes in below $145M, it could challenge the bullish outlook and raise concerns about market demand.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Veracyte can maintain its growth trajectory and meet or exceed market expectations.

Bull Confirmed If

An EPS of $0.45 or higher would confirm the bull case and suggest strong operational momentum.

Bear Confirmed If

An EPS below $0.35 would confirm the bear case, indicating potential issues with sales or market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±17.32%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened investor uncertainty about the upcoming earnings report.

Options are pricing ±17.3% while VCYT has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

80.2%

Calls (4K)P/C Ratio: 0.00Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Veracyte beats expectations, history suggests the stock could rise by around 0.09% on the first day, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to minimal movement as investors await further commentary.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop based on past earnings reactions.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on any new product launches or expansions into new markets.
2Updates on partnerships or collaborations that could enhance growth.
3Insights into customer feedback and market reception of existing products.
4Any commentary on operational efficiencies and cost management strategies.
5Management's outlook on future revenue growth and market trends.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Veracyte, Inc. is a biotechnology company focused on improving patient outcomes through genomic diagnostics....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and is closely watched by investors.

$0.41

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products.

$147M

Wall Street expectations, options signals, track record, and call prep available with Pro.

VCYT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+367.92%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In Q1-2026, Veracyte reported an EPS of $0.52, significantly exceeding analyst expectations. The stock reacted negatively, declining 1.43% the following day despite the strong earnings.

Management Promises & Guidance

Continued focus on expanding its product offerings.
Commitment to improving operational efficiencies.
Plans to enhance market penetration in existing and new territories.

Expectations

Wall Street Expectations

Bull Case

If Veracyte beats EPS and revenue estimates, it could reinforce investor confidence and lead to a significant stock price increase, similar to past performance.

Bear Case

Conversely, if the company fails to meet expectations, it could trigger a sell-off, especially given the high implied volatility in the options market.

Key Metrics to Watch

EPS

$0.41

Earnings per share is a key indicator of profitability and is closely watched by investors.

Revenue

$147M

Total revenue gives insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Veracyte's EPS exceed the consensus estimate of $0.41?

Given the company's strong track record of beating EPS estimates, this will be a critical measure of ongoing operational success.

What revenue figure will Veracyte report, and how does it compare to the consensus of $147M?

Revenue performance is essential for assessing market demand and growth potential, especially in a competitive biotech landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Veracyte's ability to leverage its recent innovations and market presence to drive higher-than-expected revenue growth this quarter.

Supporting Evidence

Veracyte has consistently beaten EPS estimates, indicating strong operational execution.

The options market's high implied volatility suggests that investors are anticipating significant movement, which could favor a positive surprise.

Recent trends in the biotech sector show increasing demand for diagnostic tests, which could benefit Veracyte.

Key Risk

If revenue comes in below $145M, it could challenge the bullish outlook and raise concerns about market demand.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Veracyte can maintain its growth trajectory and meet or exceed market expectations.

Bull Confirmed If

An EPS of $0.45 or higher would confirm the bull case and suggest strong operational momentum.

Bear Confirmed If

An EPS below $0.35 would confirm the bear case, indicating potential issues with sales or market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±17.32%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened investor uncertainty about the upcoming earnings report.

Options are pricing ±17.3% while VCYT has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

80.2%

Calls (4K)P/C Ratio: 0.00Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Veracyte beats expectations, history suggests the stock could rise by around 0.09% on the first day, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to minimal movement as investors await further commentary.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop based on past earnings reactions.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on any new product launches or expansions into new markets.
2Updates on partnerships or collaborations that could enhance growth.
3Insights into customer feedback and market reception of existing products.
4Any commentary on operational efficiencies and cost management strategies.
5Management's outlook on future revenue growth and market trends.